| Identification | Back Directory | [Name]
LARIXYL ACETATE | [CAS]
4608-49-5 | [Synonyms]
LARIXYL ACETATE
6-Acetyllarixol
Larixyl acetate
(Larix-6-yl monoacetate)
(13S)-6α-Acetoxylabda-8(17),14-diene-13-ol
[13S,(+)]-Labda-8(17),14-diene-6α,13-diol 6-acetate
(αS,1S,4S,4aS,8aR)-4-(Acetyloxy)-α-ethenyldecahydro-α,5,5,8a-tetramethyl-2-methylene-1-naphthalenepropanol
1-Naphthalenepropanol, 4-(acetyloxy)-α-ethenyldecahydro-α,5,5,8a-tetramethyl-2-methylene-, (αS,1S,4S,4aS,8aR)-
(1S,8aβ)-4α-[(S)-3-Methyl-3-hydroxy-4-pentenyl]decahydro-4aα,8,8-trimethyl-3-methylenenaphthalen-1β-ol 1-acetate
(1S,8aβ)-4α-[(S)-3-Methyl-3-hydroxy-4-pentenyl]decahydro-4aα,8,8-trimethyl-3-methylenenaphthalene-1β-ol 1-acetate
Larixyl acetate,TRP Channel,inhibit,Transient receptor potential channels,Inhibitor,systemic endothelial dysfunction,Human papillomavirus,HPV,HEK 293,Larixyl | [Molecular Formula]
C22H36O3 | [MDL Number]
MFCD08460271 | [MOL File]
4608-49-5.mol | [Molecular Weight]
348.52 |
| Chemical Properties | Back Directory | [Melting point ]
82℃ | [Boiling point ]
419.3±28.0 °C(Predicted) | [density ]
1.00±0.1 g/cm3 (20 ºC 760 Torr) | [refractive index ]
1.4826 (589.3 nm, 20℃) | [storage temp. ]
-20°C | [solubility ]
Chloroform (Slightly), Ethyl Acetate (Slightly) | [form ]
Solid | [pka]
14.47±0.29(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic | [InChI]
1S/C22H36O3/c1-8-21(6,25-16(3)23)13-10-17-15(2)14-18(24)19-20(4,5)11-9-12-22(17,19)7/h8,17-19,24H,1-2,9-14H2,3-7H3/t17-,18-,19-,21+,22+/m0/s1 | [InChIKey]
BSXKTJYNJOKMRN-TZWCSUAMSA-N | [SMILES]
CC(=O)O[C@H]1CC(=C)[C@H](CC[C@](C)(O)C=C)[C@@]2(C)CCCC(C)(C)[C@H]12 |
| Hazard Information | Back Directory | [Uses]
Larixyl Acetate has pharmacological activity determined though in vitro anti-inflammatory activity of larch (Larix decidua L.) sawdust (Erratum). | [in vivo]
Larixyl acetate (5 mg/kg, i.p., once dailly for 7 days) significantly improves aortic endothelial dysfunction in TBI mice by inhibiting TRPC6 activity, particularly enhancing acetylcholine-induced dilation[3].
Larixyl acetate (5 mg/kg, i.p., once daily for 4 weeks) improves cardiac function in pressure overload-induced heart failure model by inhibiting TRPC6, reducing cardiac hypertrophy, fibrosis, and apoptosis[4]. | Animal Model: | Closed-head mild traumatic brain injury (mTBI) model, C57BL/6, 129S, 129S-C57BL/6-F2 mice, TRPC6 knockout mice[3] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection (i.p.), once daily for 7 days | | Result: | Significantly improved aortic endothelial function 7 days after TBI.
Caused that acetylcholine (10 μM) induced dilation was significantly enhanced in Larixyl acetate-treated mice (In C57BL/6 mice, the Larixyl acetate group showed 96.9 %; in 129S-C57BL/6-F2 mice, the Larixyl acetate group showed 89.2 %). |
| Animal Model: | Transverse aortic constriction (Tac) model for pressure overload-induced heart failure in mice[5] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection (i.p.), once daily for 4 weeks | | Result: | Significantly reduced cardiac hypertrophy, left ventricular pressure, and improved cardiac function (FS and EF increased).
Improved TAC-induced cardiac fibrosis, cardiomyocyte apoptosis, and inhibited ER stress-related proteins (e.g., GRP78) expression. |
| [IC 50]
hTRPC6: 0.58 μM (IC50); hTRPC3: 6.83 μM (IC50) | [storage]
-20°C |
|
|